| Dr Michael Cody Curry, MD | |
|
919 Colony Dr, Ada, OK 74820-2329 | |
| (580) 235-0299 | |
| (580) 235-0297 |
| Full Name | Dr Michael Cody Curry |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 13 Years |
| Location | 919 Colony Dr, Ada, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144515016 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 557686 (Texas) | Secondary |
| 207X00000X | Orthopaedic Surgery | 32109 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mays Housecall Home Health Of Ada, Llc | Ada, OK | Home health agency |
| Tendercare Home Health | Coalgate, OK | Home health agency |
| Mercy Hospital Ada | Ada, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Curry Orthopedics And Sports Medicine Pllc | 4981020328 | 3 |
News Archive
IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.
Bob Hall was recovering from yet another surgery in March 2014 when a volunteer walked into his hospital room. It had been a rocky recovery since his lung transplant three months earlier at the William S. Middleton Memorial Veterans Hospital in Madison, Wis.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
› Verified 9 days ago
| Entity Name | Mercy Clinic Oklahoma Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386874550 PECOS PAC ID: 1153468921 Enrollment ID: O20091027000755 |
News Archive
IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.
Bob Hall was recovering from yet another surgery in March 2014 when a volunteer walked into his hospital room. It had been a rocky recovery since his lung transplant three months earlier at the William S. Middleton Memorial Veterans Hospital in Madison, Wis.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
› Verified 9 days ago
| Entity Name | Urgent Care Of Ada Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922313436 PECOS PAC ID: 4789700212 Enrollment ID: O20100922000182 |
News Archive
IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.
Bob Hall was recovering from yet another surgery in March 2014 when a volunteer walked into his hospital room. It had been a rocky recovery since his lung transplant three months earlier at the William S. Middleton Memorial Veterans Hospital in Madison, Wis.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
› Verified 9 days ago
| Entity Name | Primary Care Of Ada, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851744312 PECOS PAC ID: 8022392828 Enrollment ID: O20170222002032 |
News Archive
IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.
Bob Hall was recovering from yet another surgery in March 2014 when a volunteer walked into his hospital room. It had been a rocky recovery since his lung transplant three months earlier at the William S. Middleton Memorial Veterans Hospital in Madison, Wis.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
› Verified 9 days ago
| Entity Name | Curry Orthopedics And Sports Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578103727 PECOS PAC ID: 4981020328 Enrollment ID: O20200817002222 |
News Archive
IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.
Bob Hall was recovering from yet another surgery in March 2014 when a volunteer walked into his hospital room. It had been a rocky recovery since his lung transplant three months earlier at the William S. Middleton Memorial Veterans Hospital in Madison, Wis.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Cody Curry, MD 919 Colony Dr, Ada, OK 74820-2329 Ph: (580) 235-0299 | Dr Michael Cody Curry, MD 919 Colony Dr, Ada, OK 74820-2329 Ph: (580) 235-0299 |
News Archive
IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.
Bob Hall was recovering from yet another surgery in March 2014 when a volunteer walked into his hospital room. It had been a rocky recovery since his lung transplant three months earlier at the William S. Middleton Memorial Veterans Hospital in Madison, Wis.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
› Verified 9 days ago
Dr. Michael P Giovan, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3101 Arlington St # B, Ada, OK 74820 Phone: 580-332-9100 Fax: 580-332-8554 | |
Dr. Roger John Charboneau, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-559-0510 Fax: 580-272-2715 |